Global Glucagon Like Peptide 2 Receptor Market Insights, Forecast to 2025

Table of Contents

1 Study Coverage

• 1.1 Glucagon Like Peptide 2 Receptor Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Glucagon Like Peptide 2 Receptor Market Size Growth Rate by Product
  • 1.4.2 FE-203799
  • 1.4.3 Glepaglutide
  • 1.4.4 GXG-8
  • 1.4.5 HM-15910
  • 1.4.6 Others
• 1.5 Market by End User
  • 1.5.1 Global Glucagon Like Peptide 2 Receptor Market Size Growth Rate by End User
  • 1.5.2 Short Bowel Syndrome
  • 1.5.3 Diabetes
  • 1.5.4 Diarrhea
  • 1.5.5 Obesity
  • 1.5.6 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Glucagon Like Peptide 2 Receptor Market Size
  • 2.1.1 Global Glucagon Like Peptide 2 Receptor Revenue 2014-2025
  • 2.1.2 Global Glucagon Like Peptide 2 Receptor Sales 2014-2025
• 2.2 Glucagon Like Peptide 2 Receptor Growth Rate by Regions
  • 2.2.1 Global Glucagon Like Peptide 2 Receptor Sales by Regions
  • 2.2.2 Global Glucagon Like Peptide 2 Receptor Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Glucagon Like Peptide 2 Receptor Sales by Manufacturers
  • 3.1.1 Glucagon Like Peptide 2 Receptor Sales by Manufacturers
  • 3.1.2 Glucagon Like Peptide 2 Receptor Sales Market Share by Manufacturers
  • 3.1.3 Global Glucagon Like Peptide 2 Receptor Market Concentration Ratio (CR5 and HHI)
• 3.2 Glucagon Like Peptide 2 Receptor Revenue by Manufacturers
  • 3.2.1 Glucagon Like Peptide 2 Receptor Revenue by Manufacturers (2014-2019)
  • 3.2.2 Glucagon Like Peptide 2 Receptor Revenue Share by Manufacturers (2014-2019)
• 3.3 Glucagon Like Peptide 2 Receptor Price by Manufacturers
• 3.4 Glucagon Like Peptide 2 Receptor Manufacturing Base Distribution, Product Types
  • 3.4.1 Glucagon Like Peptide 2 Receptor Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Glucagon Like Peptide 2 Receptor Product Type
  • 3.4.3 Date of International Manufacturers Enter into Glucagon Like Peptide 2 Receptor Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Glucagon Like Peptide 2 Receptor Sales by Product
• 4.2 Global Glucagon Like Peptide 2 Receptor Revenue by Product
• 4.3 Glucagon Like Peptide 2 Receptor Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Glucagon Like Peptide 2 Receptor Breakdown Data by End User

6 North America

• 6.1 North America Glucagon Like Peptide 2 Receptor by Countries
  • 6.1.1 North America Glucagon Like Peptide 2 Receptor Sales by Countries
  • 6.1.2 North America Glucagon Like Peptide 2 Receptor Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Glucagon Like Peptide 2 Receptor by Product
• 6.3 North America Glucagon Like Peptide 2 Receptor by End User

7 Europe

• 7.1 Europe Glucagon Like Peptide 2 Receptor by Countries
  • 7.1.1 Europe Glucagon Like Peptide 2 Receptor Sales by Countries
  • 7.1.2 Europe Glucagon Like Peptide 2 Receptor Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Glucagon Like Peptide 2 Receptor by Product
• 7.3 Europe Glucagon Like Peptide 2 Receptor by End User

8 Asia Pacific

• 8.1 Asia Pacific Glucagon Like Peptide 2 Receptor by Countries
  • 8.1.1 Asia Pacific Glucagon Like Peptide 2 Receptor Sales by Countries
  • 8.1.2 Asia Pacific Glucagon Like Peptide 2 Receptor Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Glucagon Like Peptide 2 Receptor by Product
• 8.3 Asia Pacific Glucagon Like Peptide 2 Receptor by End User

9 Central & South America

• 9.1 Central & South America Glucagon Like Peptide 2 Receptor by Countries
  • 9.1.1 Central & South America Glucagon Like Peptide 2 Receptor Sales by Countries
  • 9.1.2 Central & South America Glucagon Like Peptide 2 Receptor Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Glucagon Like Peptide 2 Receptor by Product
• 9.3 Central & South America Glucagon Like Peptide 2 Receptor by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Glucagon Like Peptide 2 Receptor by Countries
  • 10.1.1 Middle East and Africa Glucagon Like Peptide 2 Receptor Sales by Countries
  • 10.1.2 Middle East and Africa Glucagon Like Peptide 2 Receptor Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Glucagon Like Peptide 2 Receptor by Product
• 10.3 Middle East and Africa Glucagon Like Peptide 2 Receptor by End User

11 Company Profiles

• 11.1 Hanmi Pharmaceuticals Co Ltd
  • 11.1.1 Hanmi Pharmaceuticals Co Ltd Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Hanmi Pharmaceuticals Co Ltd Glucagon Like Peptide 2 Receptor Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Hanmi Pharmaceuticals Co Ltd Glucagon Like Peptide 2 Receptor Products Offered
  • 11.1.5 Hanmi Pharmaceuticals Co Ltd Recent Development
• 11.2 Naia Ltd
  • 11.2.1 Naia Ltd Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Naia Ltd Glucagon Like Peptide 2 Receptor Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Naia Ltd Glucagon Like Peptide 2 Receptor Products Offered
  • 11.2.5 Naia Ltd Recent Development
• 11.3 Shire Plc
  • 11.3.1 Shire Plc Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Shire Plc Glucagon Like Peptide 2 Receptor Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Shire Plc Glucagon Like Peptide 2 Receptor Products Offered
  • 11.3.5 Shire Plc Recent Development
• 11.4 Tasly Pharmaceutical Group Co Ltd
  • 11.4.1 Tasly Pharmaceutical Group Co Ltd Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Tasly Pharmaceutical Group Co Ltd Glucagon Like Peptide 2 Receptor Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Tasly Pharmaceutical Group Co Ltd Glucagon Like Peptide 2 Receptor Products Offered
  • 11.4.5 Tasly Pharmaceutical Group Co Ltd Recent Development
• 11.5 Zealand Pharma AS
  • 11.5.1 Zealand Pharma AS Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Zealand Pharma AS Glucagon Like Peptide 2 Receptor Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Zealand Pharma AS Glucagon Like Peptide 2 Receptor Products Offered
  • 11.5.5 Zealand Pharma AS Recent Development

12 Future Forecast

• 12.1 Glucagon Like Peptide 2 Receptor Market Forecast by Regions
  • 12.1.1 Global Glucagon Like Peptide 2 Receptor Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Glucagon Like Peptide 2 Receptor Revenue Forecast by Regions 2019-2025
• 12.2 Glucagon Like Peptide 2 Receptor Market Forecast by Product
  • 12.2.1 Global Glucagon Like Peptide 2 Receptor Sales Forecast by Product 2019-2025
  • 12.2.2 Global Glucagon Like Peptide 2 Receptor Revenue Forecast by Product 2019-2025
• 12.3 Glucagon Like Peptide 2 Receptor Market Forecast by End User
• 12.4 North America Glucagon Like Peptide 2 Receptor Forecast
• 12.5 Europe Glucagon Like Peptide 2 Receptor Forecast
• 12.6 Asia Pacific Glucagon Like Peptide 2 Receptor Forecast
• 12.7 Central & South America Glucagon Like Peptide 2 Receptor Forecast
• 12.8 Middle East and Africa Glucagon Like Peptide 2 Receptor Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Glucagon Like Peptide 2 Receptor Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details